322 related articles for article (PubMed ID: 10627423)
1. Effect of osteoprotegerin and osteoprotegerin ligand on osteoclast formation by arthroplasty membrane derived macrophages.
Itonaga I; Sabokbar A; Murray DW; Athanasou NA
Ann Rheum Dis; 2000 Jan; 59(1):26-31. PubMed ID: 10627423
[TBL] [Abstract][Full Text] [Related]
2. Rheumatoid arthritis synovial macrophage-osteoclast differentiation is osteoprotegerin ligand-dependent.
Itonaga I; Fujikawa Y; Sabokbar A; Murray DW; Athanasou NA
J Pathol; 2000 Sep; 192(1):97-104. PubMed ID: 10951406
[TBL] [Abstract][Full Text] [Related]
3. Osteoprotegerin and osteoprotegerin ligand effects on osteoclast formation from human peripheral blood mononuclear cell precursors.
Shalhoub V; Faust J; Boyle WJ; Dunstan CR; Kelley M; Kaufman S; Scully S; Van G; Lacey DL
J Cell Biochem; 1999 Feb; 72(2):251-61. PubMed ID: 10022507
[TBL] [Abstract][Full Text] [Related]
4. Two distinct cellular mechanisms of osteoclast formation and bone resorption in periprosthetic osteolysis.
Sabokbar A; Kudo O; Athanasou NA
J Orthop Res; 2003 Jan; 21(1):73-80. PubMed ID: 12507582
[TBL] [Abstract][Full Text] [Related]
5. Arthroplasty membrane-derived fibroblasts directly induce osteoclast formation and osteolysis in aseptic loosening.
Sabokbar A; Itonaga I; Sun SG; Kudo O; Athanasou NA
J Orthop Res; 2005 May; 23(3):511-9. PubMed ID: 15885469
[TBL] [Abstract][Full Text] [Related]
6. Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption.
Michael H; Härkönen PL; Väänänen HK; Hentunen TA
J Bone Miner Res; 2005 Dec; 20(12):2224-32. PubMed ID: 16294275
[TBL] [Abstract][Full Text] [Related]
7. Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kappaB in giant cell tumor of bone: possible involvement in tumor cell-induced osteoclast-like cell formation.
Huang L; Xu J; Wood DJ; Zheng MH
Am J Pathol; 2000 Mar; 156(3):761-7. PubMed ID: 10702390
[TBL] [Abstract][Full Text] [Related]
8. Human arthroplasty derived macrophages differentiate into osteoclastic bone resorbing cells.
Sabokbar A; Fujikawa Y; Neale S; Murray DW; Athanasou NA
Ann Rheum Dis; 1997 Jul; 56(7):414-20. PubMed ID: 9486003
[TBL] [Abstract][Full Text] [Related]
9. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts.
Burgess TL; Qian Y; Kaufman S; Ring BD; Van G; Capparelli C; Kelley M; Hsu H; Boyle WJ; Dunstan CR; Hu S; Lacey DL
J Cell Biol; 1999 May; 145(3):527-38. PubMed ID: 10225954
[TBL] [Abstract][Full Text] [Related]
10. Age of donor alters the effect of cyclic hydrostatic pressure on production by human macrophages and osteoblasts of sRANKL, OPG and RANK.
Evans CE; Mylchreest S; Andrew JG
BMC Musculoskelet Disord; 2006 Mar; 7():21. PubMed ID: 16519799
[TBL] [Abstract][Full Text] [Related]
11. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
[TBL] [Abstract][Full Text] [Related]
12. Regulation of osteoclast differentiation and function by receptor activator of NFkB ligand and osteoprotegerin.
Shiotani A; Takami M; Itoh K; Shibasaki Y; Sasaki T
Anat Rec; 2002 Oct; 268(2):137-46. PubMed ID: 12221720
[TBL] [Abstract][Full Text] [Related]
13. Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo.
Lacey DL; Tan HL; Lu J; Kaufman S; Van G; Qiu W; Rattan A; Scully S; Fletcher F; Juan T; Kelley M; Burgess TL; Boyle WJ; Polverino AJ
Am J Pathol; 2000 Aug; 157(2):435-48. PubMed ID: 10934148
[TBL] [Abstract][Full Text] [Related]
14. Modulation of the effects of osteoprotegerin (OPG) ligand in a human leukemic cell line by OPG and calcitonin.
Mancini L; Moradi-Bidhendi N; Brandi ML; Perretti M; MacIntyre I
Biochem Biophys Res Commun; 2000 Dec; 279(2):391-7. PubMed ID: 11118297
[TBL] [Abstract][Full Text] [Related]
15. Roles of macrophage-colony stimulating factor and osteoclast differentiation factor in osteoclastogenesis.
Tsurukai T; Udagawa N; Matsuzaki K; Takahashi N; Suda T
J Bone Miner Metab; 2000; 18(4):177-84. PubMed ID: 10874596
[TBL] [Abstract][Full Text] [Related]
16. Osteoclast differentiation from circulating mononuclear precursors in Paget's disease is hypersensitive to 1,25-dihydroxyvitamin D(3) and RANKL.
Neale SD; Smith R; Wass JA; Athanasou NA
Bone; 2000 Sep; 27(3):409-16. PubMed ID: 10962353
[TBL] [Abstract][Full Text] [Related]
17. Tumor necrosis factor-alpha cooperates with receptor activator of nuclear factor kappaB ligand in generation of osteoclasts in stromal cell-depleted rat bone marrow cell culture.
Komine M; Kukita A; Kukita T; Ogata Y; Hotokebuchi T; Kohashi O
Bone; 2001 May; 28(5):474-83. PubMed ID: 11344046
[TBL] [Abstract][Full Text] [Related]
18. Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment.
Giuliani N; Bataille R; Mancini C; Lazzaretti M; Barillé S
Blood; 2001 Dec; 98(13):3527-33. PubMed ID: 11739153
[TBL] [Abstract][Full Text] [Related]
19. Receptor activator of nuclear factor kappaB ligand is expressed in resident and inflammatory cells in aseptic and septic prosthesis loosening.
Gehrke T; Sers C; Morawietz L; Fernahl G; Neidel J; Frommelt L; Krenn V
Scand J Rheumatol; 2003; 32(5):287-94. PubMed ID: 14690142
[TBL] [Abstract][Full Text] [Related]
20. Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function.
Udagawa N; Takahashi N; Yasuda H; Mizuno A; Itoh K; Ueno Y; Shinki T; Gillespie MT; Martin TJ; Higashio K; Suda T
Endocrinology; 2000 Sep; 141(9):3478-84. PubMed ID: 10965921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
